Vericiguat is a novel sGC stimulator that numerous cardiovascular studies and clinical trials have confirmed to lower cardiovascular mortality, risk of heart failure hospitalization, and incidence of worsening events in heart failure (4, 5). This evidence concerns the gene SGCB and heart failure.